Premature ejaculation (PE) is the most common form of male sexual dysfunction, and published objective data is not sufficient to define evidence-based medicine for secondary PE. But nothing more than the following: short ejaculation latency, poor ejaculation control, and consequent low mood, can be divided into primary and secondary, recently, also proposed natural variability PE and premature ejaculation dysfunction 2 kinds of PE,[2,3] but their specific role has not been clarified. Because of the specificity of the disease, there is currently no systematic assessment of primary PE and secondary PE, but most studies believe that the prevalence is between 20% and 30%.[4,5] The prevalence of PE has nothing to do with age, more common in black, Spanish men, and men in Islamic backgrounds,[7,8] and the prevalence of PE in men with lower education levels may be higher. At present, the cause of premature ejaculation is still unclear. The mainstream view is that it may be related to serotonin neurotransmitter disorder, excessive penile head sensitivity, genetic variation, prostatitis, thyroid disease, and emotional factors.[14,15] PE can have a great psychological impact on patients, leading to mental distress, anxiety, and depression, which in turn has a major impact on the quality of life of patients.
The treatment of premature ejaculation should emphasize the implementation of personalized comprehensive treatment according to the classification diagnosis of patients’ diseases and different causes to improve the satisfaction of patients and partners. At present, the treatment of premature ejaculation includes medical treatment, behavioral psychotherapy, surgical treatment, and Chinese medicine treatment. Surgical treatment is still in the exploratory stage. Oral 5-HT receptor reuptake inhibitors (SSRIs) for the treatment of premature ejaculation are widely used in clinical applications, and can delay ejaculation to some extent, but have certain side effects, including nausea and diarrhea, headache, dizziness, decreased libido, no ejaculation, and erectile dysfunction.[17,18] At the same time, the vast majority of psychotherapy outcomes are uncontrolled, single-blind, and few studies that meet the requirements of evidence-based medicine, the efficacy of behavioral therapy is difficult to maintain for a long time.[20,21]
In recent years, the application of acupuncture therapy has become more and more extensive, and clinically satisfactory treatment results have been obtained, but most of them are limited to clinical efficacy observation, based on the personal experience or preference of clinicians, lack of evidence-based exploration. This study used the method of mesh meta-analysis to directly or indirectly compare the efficacy of various acupuncture therapies and other therapies, and to sort the therapeutic effects, in order to provide evidence-based basis for the clinical decision-making of PE.
This is a systematic review and ethical approval was not necessary.
2.1 Study registration
Study protocol has been registered on PROSPERO CRD42018111661. (http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018111661).
2.2 Eligibility criteria
2.2.1 Type of study
All randomized controlled trials that investigate the effectiveness of ACU treatments for PE will be included.
Patients must be over 18, any gender, disease stage, or severity.
The 2 groups of interventions are respectively the following treatment options: acupuncture combined with drug therapy or single acupuncture therapy (needle, moxibustion, cans, bee needles, fire needles, etc.), or comprehensive acupuncture therapy (needle, moxibustion, cans, bee needles, fire needles). Two or more acupuncture treatments; the use of materials, treatment sites, treatment time, and treatment are not limited, ACU treatment and drug treatment combined with the need to use the same drug treatment in the intervention group and the comparison group.
2.2.4 Inclusion and exclusion criteria
126.96.36.199 Inclusion criteria
Study types were randomized or quasi-randomized controlled trials, whether or not blinded. The document language is limited to Chinese and English. The 2 groups of interventions are any of the following treatment options: or single acupuncture therapy (needle, moxibustion, cans, bee needles, fire needles, etc.), or comprehensive acupuncture therapy (needle, moxibustion, cans, bee needles, fire needles, etc.). Therapy, the use of materials, treatment sites, treatment time, and treatment are not limited. Outcome indicators contain total efficiency.
188.8.131.52 Exclusion criteria
Nonrandomized controlled clinical studies literature. Animal experiments, reviews, conference papers, etc will be excluded. The treatment plan involves other treatments such as traction, massage, and Chinese medicine. The results of the study are unclear and the research data is not detailed.
The primary outcome measure is the intravaginal ejaculation latency (IELT), which is the time from when the penis is inserted into the vagina until the beginning of ejaculation. Secondary outcome measures were the Premature Effusion Diagnostic Tool (PEDT), the Arab Premature Eradication Index (AIPE), and the Premature Effusion Index (IPE). Each item of PEDT ranges from 0 (no problem) to 4 (very serious problem). The higher the score, the more severe the symptoms; AIPE and IPE are the opposite.
2.2.6 Data source
Search online databases such as PubMed, Embase, Cochrane Library, China Biomedical Literature (CBM), China Knowledge Network (CNKI), VIP (VIP), Wanfang, etc., and collect acupuncture treatment of PE-related RCTs from October 2018. At the same time we will manually search conference proceedings, and the World Health Organization International Clinical Trial Registration Platform (ICTRP), ClinicalTrials.gov and the China Clinical Trial Registry. Search strategies will be performed as outlined in the Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0.
2.2.7 Study selection
Data screening and extraction will be performed using EntNeX X6, EPDATA 3.1 and Excel 2013. Two researchers independently searched the above databases, read the topics and abstracts, removed the documents that did not meet the inclusion criteria, read the remaining documents in full, and determined the final eligible studies in strict accordance with the inclusion and exclusion criteria, such as 2 researchers. If there is a dispute between them, the decision will be discussed with the third researcher.
The extracted information includes: first author, publication year, sample size, total effective rate, randomized study and blinded information, return visits during study, shedding, and adverse reactions.
2.2.8 Risk of bias
The literature quality assessment will be assessed using the Cochrane website's Risk of Bias (ROB) assessment tool. Evaluation criteria included random sequence generation (select bias), allocation concealment (select bias), results assessment blind detection (detection bias), incomplete outcome data (loss bias), selective reporting (report bias), and other biases. Two evaluators independently screened the literature according to the predetermined inclusion criteria and resolved the differences through discussion or a third researcher's assistance. If the data is missing, contact the author of the literature to obtain relevant information. According to the special data extraction form of this subject, one researcher extracts and enters the data, the other checks, uses the discussion to resolve the differences, and the lack of information is supplemented by the author of the literature communication.
2.2.9 Statistical analysis
Statistical analysis was performed using the Bayesian model-based ADDIS software.[24,25] Direct comparisons were performed using the Q test and I2 for heterogeneity testing. The odds ratio (OR) is used for the 2-class effect size, and the standardized mean difference (SMD) is used for the continuity effect. The 95% confidence interval (CI) is used. The mesh meta-analysis used a consistency model with a statistical significance of P < .05. The inconsistency test uses a node analysis model (i.e., the point method). If P > .05, there is no evidence to prove that there is inconsistency in the study. The convergence of the mesh Meta is tested by the potential scale reduction parameter (PSRF). If the PSRF is close to 1, it means that the convergence of this study is good, and the conclusion of the meta-analysis is reliable.
2.2.10 Quality of evidence
This study will use the GRADE pro online software to evaluate the included studies.
The cause of PE has not been fully clarified.[26,27] It is currently believed that the disease may have the following pathogenic factors: psychological reasons: self-confidence, uneasiness, loss of self-confidence in sexual intercourse. Organic causes: due to penile hypersensitivity or increased sensory nerve excitability, the ejaculation center is caused by the dysfunctional function of the penis. Others: such as dermatitis, balanitis, prostatitis, seminal vesiculitis, urethritis and other inflammatory diseases, sympathetic ganglia damage, polycythemia, drug withdrawal syndrome. Due to the uncertainty of its etiology, treatment methods are also diversified. For example, sexy concentration training is the most representative program in psychotherapy, and a satisfactory success rate has been achieved. However, due to the long-term close cooperation of the woman. The study found that local anesthetics (such as lidocaine-propylaminocaine cream) can reduce the sensitivity of the glans and prolong the IELT, but its spread can cause numbness to the vaginal wall of the spouse, which limits its wide application. Some surgical methods, such as penile prosthesis implantation and penile dorsal nerve resection, have begun trials in some countries, but their safety and effectiveness have yet to be further studied. Selective 5-HT reuptake inhibitors (SSRIs) were originally drugs for the treatment of depression, with varying degrees of delayed ejaculation, have been shown to have a definite therapeutic effect on the disease, and have been identified as the drug of choice for the treatment of this disease. Such drugs include citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline, which have similar drug mechanisms, can extend IELT to varying degrees, and improve the sexual life satisfaction of patients and spouses. Among them, paroxetine is the most effective, and some studies have found that after treatment, the patient's IELT can be extended by 8 times. However, these drugs generally have many adverse reactions, such as fatigue, yawning, nausea, vomiting, dry mouth, and so on. As an external treatment with low side effects and environmental protection, acupuncture has long been used to treat male diseases such as erectile dysfunction and chronic prostatitis. Although acupuncture treatment of premature ejaculation lacks understanding, clinical studies have shown that acupuncture can prolong ejaculation to a certain extent. At present, the clinical evidence of acupuncture for premature ejaculation is insufficient. Most of them are the result of low quality, small samples. Therefore, we will use systematic reviews and meta-analyses to assess the efficacy and safety of acupuncture for premature ejaculation. The study also has the following defects: the minimum sample content is not estimated in the included studies, the sample size is small, and false positive or false negative results may occur; the age level is not refined in the study, the duration of the disease is different, and the intervention measures (drugs), different choices, treatment time, etc., will have a certain impact on the evaluation results, which will affect the results and the strength of their argumentation.
Data curation: Hengheng Dai, Jisheng Wang.
Formal analysis: Binghao Bao, Yubing Yan.
Funding acquisition: Haisong Li.
Project administration: Bin Wang.
Supervision: Song Sun, Bin Wang.
Validation: Haisong Li.
Writing – original draft: Hengheng Dai, Jisheng Wang.
Writing – review & editing: Binghao Bao, Song Sun.
. McMahon CG, Althof SE, Waldinger MD, et al. An evidence based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine (ISSM) ad hoc committee for the definition of premature ejaculation. J Sex Med 2008;5:1590–606.
. Waldinger MD, Schweitzer DH. Changing paradigms from an historical DSM-III and DSM-IV view towards an evidence based definition of premature ejaculation. Part I: Validity of DSM-IV-TR. J Sex Med 2006;3:682–92.
. Waldinger MD. Premature ejaculation: state of the art. Urol ClinNorth Am 2007;34:591–9.
. Waldinger MD. The need for a revival of psychoanalytic investigations into premature ejaculation. J Mens Health Gend 2006;3:390–6.
. St Lawrence JS, Madakasira S. Evaluation and treatment of premature ejaculation: a critical review. Int J Psychiatr Med 1992;22:77–97.
. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537–44.
. Carson C, Gunn K. Premature ejaculation: definition and prevalence. Int J Impot Res 2006;18(suppl 1):S5–13.
. Richardson D, Goldmeier D. Premature ejaculation—does country of origin tell us anything about etiology? J Sex Med 2005;2:508–12.
. Laumann EO, Nicolosi A, Glasser DB, et al. Sexual problems among women and men aged 40–80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res 2005;17:39–57.
. Waldinger MD. The neurobiological approach to premature ejaculation. J Urol 2002;168:2359–67.
. Zhang HF, Zhang CY, Li XH, et al. Dorsal penile nerves and primary premature ejaculation. Chin Med J 2009;122:3017.
. Jern P, et al. Premature and delayed ejaculation: genetic and environmental effects in a population-based sample of finnish twins. J Sex Med 2010;4:1739–49.
. Lee JH, Lee SW. Relationship between premature ejaculation and chronic prostatitis/chronic pelvic pain syndrome. J Sex Med 2015;12:697–704.
. Carani C, Isidori AM, Granata A, et al. Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. J Clin Endocrinol Metab 2005;90:6472–9.
. Corona G, Petrone L, Mannucci E, et al. Psycho-biological correlates of rapid ejaculation in patients attending an andrologic unit for sexual dysfunctions. Eur Urol 2004;46:615–22.
. Giuliano F. 5-Hydroxytryptamine in premature ejaculation: opportunities for therapeutic intervention. Trends Neurosci 2007;30:79–84.
. Patrick DL, Althof SE, Pryor JL, et al. Original Research—Ejaculatory disorders: premature ejaculation: an observational study of men and their partners. J Sex Med 2010;2:358–67.
. McMahon CG, Porst H. Oral agents for the treatment of premature ejaculation: review of efficacy and safety in the context of the recent International Society for Sexual Medicine criteria for lifelong premature ejaculation. J Sex Med 2011;8:2707–25.
. Althof SE. Psychological approaches to the treatment of rapid ejaculation. J Mens Health Gender 2006;3:180–6.
. De Amicis LA, Goldberg DC, Lopiccolo J, et al. Clinical follow-up of couples treated for sexual dysfunction. Arch Sex Behav 1985;14:467–89.
. Hawton K, Catalan J, Martin P, et al. Long-term outcome of sex therapy. Behav Res Ther 1986;24:665–75.
. Chen ZX. Control study on acupuncture
and medication for treatment of primary simple premature ejaculation. Zhongguo Zhen Jiu 2009;29:13–5.
. Useem J, Brennan A, LaValley M, et al. Systematic differences between Cochrane and non-Cochrane meta-analyses on the same topic: a matched pair analysis. PLoS One 2015;10:e0144980.
. Valkenhoef GV, Tervonen T, Zwinkels T, et al. AIDDIS: a decision support system for evidence-based medicine. Decis Support Syst 2013;55:459–75.
. Jansen JP, Crawford B, Bergman G, et al. Bayesian meta-analysis
of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 2008;11:956–64.
. Salanti G, Higgins JP, Ades AE, et al. Evaluation of networks of randomized trials. Stat Method Med Res 2008;17:279–301.
. Rowland DL, Cooper SE, Schneider M. Defining premature ejaculation for experimental and clinical investigation. Arch Sex Behav 2001;30:235–53.
. Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010;57:804–14.
. Waldinger MD, Zwinderman AH, Olivier B. Antidepressants and ejaculation: a double-blind, randomized, fix dose study with mirtazapine and paroxetine. J Clin Psychopharmacol 2003;23:467–70.